Skip to content
Screener

Novavax NVAX Business Segments — Supplier finance programs

Similar metrics at other companies

Mercado Libre logo
MELISupplier finance program
$819M+72.8%
AES logo
AESSupplier Finance Program Obligations
$805M+33.1%
Motorcar Parts of America logo
MPAASupplier Finance Program Obligations
4,207,600,000%+841,500,000pp
Terex logo
TEXSupplier Finance Program Obligations
4,400,000,000%+800,000,000pp
Kimberly-Clark logo
KMBSupplier Finance Program Obligations
100,000,000,000%0.0pp
Tyson Foods logo
TSNSupplier Finance Program Obligations
5,200,000,000%+700,000,000pp

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept nvax:ResearchAndDevelopmentExpenseSupplierFinanceProgram.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$56,698$239,240$196,212$905,895
Cost of sales14,24615,32544,94129,439
Research and development expenses:
Direct COVID-19 Vaccine(1)20,07313,07754,32828,824
Direct CIC and influenza vaccines7037,1173,55619,621
Direct other vaccine development programs(1)3,1298425,393997
Employee and benefit expenses30,82036,14968,87576,060
Facility and other research and development expenses(2)15,96822,04834,01342,668

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's business segments — supplier finance programs?
Novavax (NVAX) reported business segments — supplier finance programs of $20.07M in Q2 2026.
What does business segments — supplier finance programs mean?
This metric represents the financial obligations or liabilities associated with supply chain financing arrangements used to manage working capital and vendor payment cycles. It reflects the company's reliance on external financing structures to support procurement operations and maintain liquidity with key suppliers. Monitoring this helps investors assess the company's cash flow management strategies and potential credit risk exposure within the supply chain.

Ask your AI about Novavax's business segments — supplier finance programs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude